China NMPA Inspection - Chengdu Qingshan Likang Pharmaceutical Co., Ltd. - November 03, 2020

This document outlines notifications issued by the National Medical Products Administration (NMPA) regarding a series of unannounced inspections conducted on several companies. The regulatory framework for these actions falls under the NMPA's authority to conduct oversight of medical products and cosmetics manufacturers in China. The companies subject to these unannounced inspections include Chengdu Qingshan Likang Pharmaceutical Co., Ltd. (Notification No. 2020001), Chengdu Keluorui Cosmetics Co., Ltd. (Notification No. 2020002), Chengdu Liyan Workshop Biochemical Technology Co., Ltd. (Notification No. 2020003), Chengdu Xinglishi Cosmetics Co., Ltd. (Notification No. 2020004), Luzhou Sisi Li Daily Chemical Co., Ltd. (Notification No. 2020005), and Sichuan Rossmairi Biotechnology Co., Ltd. (Notification No. 2020006). While the document clearly identifies the inspected entities and the nature of the inspections as 'unannounced,' it does not provide specific inspection dates, details regarding any main violations or issues discovered, or any required corrective actions resulting from these inspections. The provided information solely comprises the formal notifications of these oversight activities, indicating that the NMPA initiated reviews of these companies' operations in 2020. Further details regarding the outcomes of these inspections would be found in separate, detailed reports.